Status:
UNKNOWN
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Lead Sponsor:
Targeted Therapy Technologies, LLC
Conditions:
Macula Edema
Radiation Retinopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflamm...
Detailed Description
This phase I trial will assess primarily the safety and secondarily anti-inflammatory/neovascular effect of Episcleral Celecoxib in patients suffering from macular edema \& inflammatory disorders of t...
Eligibility Criteria
Inclusion
- Age \>= 18 years;
- Visual acuity letter score in study eye \< 70 and ≥ 25 letters (approximate Snellen equivalent 20/32 to 20/320);
- Ophthalmoscopic evidence of center-involved macular edema, within the central subfield (CSF); • Inflammatory disorders of the sclera, choroid, retina or vitreous
Exclusion
- Inability to understand informed consent, cooperate with testing or return to follow up visits;
- Pregnant or lactating women;
- Co-existent ocular disorder of the cornea, lens or media that will interfere with assessment of safety or efficacy.
Key Trial Info
Start Date :
March 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04120636
Start Date
March 5 2021
End Date
June 30 2024
Last Update
November 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Medicine Ophthalmology
Palo Alto, California, United States, 94303